BAM15

BAM15 (N5,N6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine) is a synthetic small-molecule mitochondrial protonophore first identified in a 2014 phenotypic screen by Kenwood et al. at the University of Virginia and Virginia Tech for compounds that uncouple mitochondrial oxidative phosphorylation without depolarizing the plasma membrane [1]. The compound dissipates the electrochemical proton gradient across the inner mitochondrial membrane, thereby uncoupling electron transport from adenosine triphosphate (ATP) synthesis and increasing substrate oxidation and energy expenditure. Unlike the classical protonophore uncouplers 2,4-dinitrophenol (DNP) and carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP), BAM15 selectively targets the mitochondrial membrane and does not collapse the plasma membrane potential at effective uncoupling concentrations, a property that confers a substantially wider therapeutic index and reduced cytotoxicity in cultured cells and in vivo [1, 2]. The compound is orally bioavailable in mice (67 percent oral bioavailability, Cmax 8.2 micromolar, t1/2 1.7 hours) with primary distribution to the liver, supporting hepatic metabolic applications [3]. In C57BL/6J mice fed a high-fat diet, BAM15 administered at 100 mg/kg/day by oral gavage reversed diet-induced obesity, decreased body fat mass without altering food intake or lean body mass, reduced hepatic triglycerides by approximately 75 percent, decreased inflammatory lipids, and improved whole-body insulin sensitivity as demonstrated by hyperinsulinemic-euglycemic clamp [3]. In a head-to-head comparison in female db/db mice, BAM15 and calorie restriction improved body weight and liver steatosis to levels superior to semaglutide, niclosamide ethanolamine (NEN), and rosiglitazone, while BAM15, semaglutide, and rosiglitazone completely restored glucose tolerance [4]. These metabolic effects are mediated through sustained activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), promoting fatty acid oxidation, glucose uptake, and mitochondrial biogenesis [2, 5]. Beyond metabolic disease, BAM15 has demonstrated preclinical efficacy in acute kidney injury and sepsis (reducing mortality even when administered 12 hours after cecal ligation and puncture in mice) [6], in acute myeloid leukemia (inhibiting AML cell proliferation and inducing reactive oxygen species-mediated apoptosis with selectivity over normal cells) [7], in sarcopenic obesity (preserving skeletal muscle contractility and mitochondrial respiration in aged mice) [8, 9], in atherosclerosis (suppressing western diet-induced plaque formation in ApoE-knockout mice through AMPK activation and NF-kappaB/NLRP3 inflammasome suppression) [10, 11], and in vascular smooth muscle relaxation [5]. Safety pharmacology in rodents has demonstrated no alteration of body temperature, food intake, lean body mass, or standard hematological and biochemical markers of toxicity at effective metabolic doses [3]. BAM15 has not entered human clinical trials as of the most recent monograph revision. The compound is supplied as a research-grade material by multiple chemical suppliers at greater than 98 percent purity and is not approved by any regulatory authority for therapeutic use. This monograph documents the chemistry, synthesis, discovery history, molecular pharmacology, pharmacokinetics, preclinical evidence base across metabolic, inflammatory, oncologic, and aging indications, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event profile, and a structured comparative assessment against five alternative mitochondrial uncouplers.